In urogenital tumors immunotherapeutic drugs have shown activity and lasting responses. Identification of ideal candidates for therapy with immune checkpoint blockade represents a challenge. The presence of tumor-infiltrating lymphocytes (TIL) might guide the selection of patients for immunotherapy.